Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

L. Peyrin-Biroulet, W. Sandborn, B. E. Sands, W. Reinisch, W. Bemelman, R. V. Bryant, G. D'Haens, I. Dotan, M. Dubinsky, B. Feagan, G. Fiorino, R. Gearry, S. Krishnareddy, P. L. Lakatos, E. V. Loftus, P. Marteau, P. Munkholm, T. B. Murdoch, I. Ordás, R. PanaccioneR. H. Riddell, J. Ruel, D. T. Rubin, M. Samaan, C. A. Siegel, M. S. Silverberg, J. Stoker, S. Schreiber, S. Travis, G. Van Assche, S. Danese, J. Panes, G. Bouguen, S. O'Donnell, B. Pariente, S. Winer, S. Hanauer, J. F. Colombel

Research output: Contribution to journalArticle

475 Citations (Scopus)

Abstract

OBJECTIVES:The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat-to-target" clinical management strategy using an evidence-based expert consensus process.METHODS:A Steering Committee of 28 IBD specialists developed recommendations based on a systematic literature review and expert opinion. Consensus was gained if ≥75% of participants scored the recommendation as 7-10 on a 10-point rating scale (where 10=agree completely).RESULTS:The group agreed upon 12 recommendations for ulcerative colitis (UC) and Crohn's disease (CD). The agreed target for UC was clinical/patient-reported outcome (PRO) remission (defined as resolution of rectal bleeding and diarrhea/altered bowel habit) and endoscopic remission (defined as a Mayo endoscopic subscore of 0-1). Histological remission was considered as an adjunctive goal. Clinical/PRO remission was also agreed upon as a target for CD and defined as resolution of abdominal pain and diarrhea/altered bowel habit; and endoscopic remission, defined as resolution of ulceration at ileocolonoscopy, or resolution of findings of inflammation on cross-sectional imaging in patients who cannot be adequately assessed with ileocolonoscopy. Biomarker remission (normal C-reactive protein (CRP) and calprotectin) was considered as an adjunctive target.CONCLUSIONS:Evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available. Prospective studies are needed to determine how these targets will change disease course and patients' quality of life.

Original languageEnglish
Pages (from-to)1324-1338
Number of pages15
JournalAmerican Journal of Gastroenterology
Volume110
Issue number9
DOIs
Publication statusPublished - Sep 10 2015

Fingerprint

Inflammatory Bowel Diseases
Consensus
Ulcerative Colitis
Crohn Disease
Habits
Diarrhea
Leukocyte L1 Antigen Complex
Therapeutics
Expert Testimony
C-Reactive Protein
Abdominal Pain
Biomarkers
Quality of Life
Organizations
Prospective Studies
Hemorrhage
Inflammation
Patient Reported Outcome Measures

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Peyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., ... Colombel, J. F. (2015). Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. American Journal of Gastroenterology, 110(9), 1324-1338. https://doi.org/10.1038/ajg.2015.233

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) : Determining Therapeutic Goals for Treat-to-Target. / Peyrin-Biroulet, L.; Sandborn, W.; Sands, B. E.; Reinisch, W.; Bemelman, W.; Bryant, R. V.; D'Haens, G.; Dotan, I.; Dubinsky, M.; Feagan, B.; Fiorino, G.; Gearry, R.; Krishnareddy, S.; Lakatos, P. L.; Loftus, E. V.; Marteau, P.; Munkholm, P.; Murdoch, T. B.; Ordás, I.; Panaccione, R.; Riddell, R. H.; Ruel, J.; Rubin, D. T.; Samaan, M.; Siegel, C. A.; Silverberg, M. S.; Stoker, J.; Schreiber, S.; Travis, S.; Van Assche, G.; Danese, S.; Panes, J.; Bouguen, G.; O'Donnell, S.; Pariente, B.; Winer, S.; Hanauer, S.; Colombel, J. F.

In: American Journal of Gastroenterology, Vol. 110, No. 9, 10.09.2015, p. 1324-1338.

Research output: Contribution to journalArticle

Peyrin-Biroulet, L, Sandborn, W, Sands, BE, Reinisch, W, Bemelman, W, Bryant, RV, D'Haens, G, Dotan, I, Dubinsky, M, Feagan, B, Fiorino, G, Gearry, R, Krishnareddy, S, Lakatos, PL, Loftus, EV, Marteau, P, Munkholm, P, Murdoch, TB, Ordás, I, Panaccione, R, Riddell, RH, Ruel, J, Rubin, DT, Samaan, M, Siegel, CA, Silverberg, MS, Stoker, J, Schreiber, S, Travis, S, Van Assche, G, Danese, S, Panes, J, Bouguen, G, O'Donnell, S, Pariente, B, Winer, S, Hanauer, S & Colombel, JF 2015, 'Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target', American Journal of Gastroenterology, vol. 110, no. 9, pp. 1324-1338. https://doi.org/10.1038/ajg.2015.233
Peyrin-Biroulet, L. ; Sandborn, W. ; Sands, B. E. ; Reinisch, W. ; Bemelman, W. ; Bryant, R. V. ; D'Haens, G. ; Dotan, I. ; Dubinsky, M. ; Feagan, B. ; Fiorino, G. ; Gearry, R. ; Krishnareddy, S. ; Lakatos, P. L. ; Loftus, E. V. ; Marteau, P. ; Munkholm, P. ; Murdoch, T. B. ; Ordás, I. ; Panaccione, R. ; Riddell, R. H. ; Ruel, J. ; Rubin, D. T. ; Samaan, M. ; Siegel, C. A. ; Silverberg, M. S. ; Stoker, J. ; Schreiber, S. ; Travis, S. ; Van Assche, G. ; Danese, S. ; Panes, J. ; Bouguen, G. ; O'Donnell, S. ; Pariente, B. ; Winer, S. ; Hanauer, S. ; Colombel, J. F. / Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) : Determining Therapeutic Goals for Treat-to-Target. In: American Journal of Gastroenterology. 2015 ; Vol. 110, No. 9. pp. 1324-1338.
@article{54f8e9243d6047a0a6861a3ede6e6186,
title = "Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target",
abstract = "OBJECTIVES:The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a {"}treat-to-target{"} clinical management strategy using an evidence-based expert consensus process.METHODS:A Steering Committee of 28 IBD specialists developed recommendations based on a systematic literature review and expert opinion. Consensus was gained if ≥75{\%} of participants scored the recommendation as 7-10 on a 10-point rating scale (where 10=agree completely).RESULTS:The group agreed upon 12 recommendations for ulcerative colitis (UC) and Crohn's disease (CD). The agreed target for UC was clinical/patient-reported outcome (PRO) remission (defined as resolution of rectal bleeding and diarrhea/altered bowel habit) and endoscopic remission (defined as a Mayo endoscopic subscore of 0-1). Histological remission was considered as an adjunctive goal. Clinical/PRO remission was also agreed upon as a target for CD and defined as resolution of abdominal pain and diarrhea/altered bowel habit; and endoscopic remission, defined as resolution of ulceration at ileocolonoscopy, or resolution of findings of inflammation on cross-sectional imaging in patients who cannot be adequately assessed with ileocolonoscopy. Biomarker remission (normal C-reactive protein (CRP) and calprotectin) was considered as an adjunctive target.CONCLUSIONS:Evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available. Prospective studies are needed to determine how these targets will change disease course and patients' quality of life.",
author = "L. Peyrin-Biroulet and W. Sandborn and Sands, {B. E.} and W. Reinisch and W. Bemelman and Bryant, {R. V.} and G. D'Haens and I. Dotan and M. Dubinsky and B. Feagan and G. Fiorino and R. Gearry and S. Krishnareddy and Lakatos, {P. L.} and Loftus, {E. V.} and P. Marteau and P. Munkholm and Murdoch, {T. B.} and I. Ord{\'a}s and R. Panaccione and Riddell, {R. H.} and J. Ruel and Rubin, {D. T.} and M. Samaan and Siegel, {C. A.} and Silverberg, {M. S.} and J. Stoker and S. Schreiber and S. Travis and {Van Assche}, G. and S. Danese and J. Panes and G. Bouguen and S. O'Donnell and B. Pariente and S. Winer and S. Hanauer and Colombel, {J. F.}",
year = "2015",
month = "9",
day = "10",
doi = "10.1038/ajg.2015.233",
language = "English",
volume = "110",
pages = "1324--1338",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)

T2 - Determining Therapeutic Goals for Treat-to-Target

AU - Peyrin-Biroulet, L.

AU - Sandborn, W.

AU - Sands, B. E.

AU - Reinisch, W.

AU - Bemelman, W.

AU - Bryant, R. V.

AU - D'Haens, G.

AU - Dotan, I.

AU - Dubinsky, M.

AU - Feagan, B.

AU - Fiorino, G.

AU - Gearry, R.

AU - Krishnareddy, S.

AU - Lakatos, P. L.

AU - Loftus, E. V.

AU - Marteau, P.

AU - Munkholm, P.

AU - Murdoch, T. B.

AU - Ordás, I.

AU - Panaccione, R.

AU - Riddell, R. H.

AU - Ruel, J.

AU - Rubin, D. T.

AU - Samaan, M.

AU - Siegel, C. A.

AU - Silverberg, M. S.

AU - Stoker, J.

AU - Schreiber, S.

AU - Travis, S.

AU - Van Assche, G.

AU - Danese, S.

AU - Panes, J.

AU - Bouguen, G.

AU - O'Donnell, S.

AU - Pariente, B.

AU - Winer, S.

AU - Hanauer, S.

AU - Colombel, J. F.

PY - 2015/9/10

Y1 - 2015/9/10

N2 - OBJECTIVES:The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat-to-target" clinical management strategy using an evidence-based expert consensus process.METHODS:A Steering Committee of 28 IBD specialists developed recommendations based on a systematic literature review and expert opinion. Consensus was gained if ≥75% of participants scored the recommendation as 7-10 on a 10-point rating scale (where 10=agree completely).RESULTS:The group agreed upon 12 recommendations for ulcerative colitis (UC) and Crohn's disease (CD). The agreed target for UC was clinical/patient-reported outcome (PRO) remission (defined as resolution of rectal bleeding and diarrhea/altered bowel habit) and endoscopic remission (defined as a Mayo endoscopic subscore of 0-1). Histological remission was considered as an adjunctive goal. Clinical/PRO remission was also agreed upon as a target for CD and defined as resolution of abdominal pain and diarrhea/altered bowel habit; and endoscopic remission, defined as resolution of ulceration at ileocolonoscopy, or resolution of findings of inflammation on cross-sectional imaging in patients who cannot be adequately assessed with ileocolonoscopy. Biomarker remission (normal C-reactive protein (CRP) and calprotectin) was considered as an adjunctive target.CONCLUSIONS:Evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available. Prospective studies are needed to determine how these targets will change disease course and patients' quality of life.

AB - OBJECTIVES:The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat-to-target" clinical management strategy using an evidence-based expert consensus process.METHODS:A Steering Committee of 28 IBD specialists developed recommendations based on a systematic literature review and expert opinion. Consensus was gained if ≥75% of participants scored the recommendation as 7-10 on a 10-point rating scale (where 10=agree completely).RESULTS:The group agreed upon 12 recommendations for ulcerative colitis (UC) and Crohn's disease (CD). The agreed target for UC was clinical/patient-reported outcome (PRO) remission (defined as resolution of rectal bleeding and diarrhea/altered bowel habit) and endoscopic remission (defined as a Mayo endoscopic subscore of 0-1). Histological remission was considered as an adjunctive goal. Clinical/PRO remission was also agreed upon as a target for CD and defined as resolution of abdominal pain and diarrhea/altered bowel habit; and endoscopic remission, defined as resolution of ulceration at ileocolonoscopy, or resolution of findings of inflammation on cross-sectional imaging in patients who cannot be adequately assessed with ileocolonoscopy. Biomarker remission (normal C-reactive protein (CRP) and calprotectin) was considered as an adjunctive target.CONCLUSIONS:Evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available. Prospective studies are needed to determine how these targets will change disease course and patients' quality of life.

UR - http://www.scopus.com/inward/record.url?scp=84941260661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941260661&partnerID=8YFLogxK

U2 - 10.1038/ajg.2015.233

DO - 10.1038/ajg.2015.233

M3 - Article

C2 - 26303131

AN - SCOPUS:84941260661

VL - 110

SP - 1324

EP - 1338

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 9

ER -